PolyPid Ltd.
PYPD
Positions held
Your positionsPYPD isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $99.53M | Enterprise value | $94.54M | Trailing P/E | — | Forward P/E | -3.99 |
| PEG | — | Price / book | 18.49 | Beta | 1.38 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -2.4% | ROA | -74.6% | Debt / equity | 0.29 |
| Current ratio | 1.35 | Free cash flow | -$17.36M | Analyst recommendation | strong_buy | Mean target | $11.75 |
| 52w high | $5.73 | 52w low | $3.06 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$7.8M | -$7.7M | -$8.5M | -$7.5M | -$10.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$7.8M | -$7.8M | -$8.5M | -$7.5M | -$9.4M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$34.2M | -$29.0M | -$23.9M | -$39.6M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$33.0M | -$28.0M | -$22.9M | -$38.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-04 · PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data
2026-10-01 · European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
2026-10-01 · PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
2026-09-15 · PolyPid Announces Participation in Upcoming Fall Investor Conferences
2026-08-19 · PolyPid (PYPD) Q2 2026 Earnings Call Transcript
2026-08-12 · PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ...
2026-08-12 · PolyPid Ltd. Q2 2026 Earnings Call Summary
2026-08-12 · PolyPid Q2 Earnings Call Highlights
2026-08-12 · PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-07-30 · PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
2026-07-29 · PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
2026-07-21 · Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid
Price (daily)
Full chart · RSI · MACD · patterns